Ra Pharmaceuticals, Inc. (RARX) Financial Statements (2026 and earlier)

Company Profile

Business Address 87 CAMBRIDGE PARK DRIVE
CAMBRIDGE, MA 02140
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments209,82270,381117,812
Cash and cash equivalent209,82270,381117,812
Other undisclosed current assets2,5852,4961,690
Total current assets:212,40772,877119,502
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization5,1655,6065,537
Intangible asset, including goodwill, after accumulated amortization314380445
Goodwill 183183183
Intangible asset, excluding goodwill, after accumulated amortization131197262
Restricted cash and investments1,3341,3341,334
Other undisclosed noncurrent assets   
Total noncurrent assets:6,8137,3207,316
TOTAL ASSETS:219,22080,197126,818
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,7228,2856,434
Accounts payable3,2454,3483,252
Accrued liabilities6,4773,9373,182
Deferred revenue and credits✕479329303
Other undisclosed current liabilities   
Total current liabilities:10,2018,6146,737
Noncurrent Liabilities
Liabilities, other than long-term debt 1,8802,3592,800
Deferred revenue and credits✕1,8802,3592,800
Other undisclosed noncurrent liabilities214059
Total noncurrent liabilities:1,9012,3992,859
Total liabilities:12,10211,0139,596
Equity
Equity, attributable to parent207,11869,184117,222
Common stock422323
Additional paid in capital395,233192,375185,963
Accumulated deficit(188,157)(123,214)(68,764)
Total equity:207,11869,184117,222
TOTAL LIABILITIES AND EQUITY:219,22080,197126,818

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues2,5006454,928
Net investment income1,464645109
Gross profit:2,5006454,928
Operating expenses(68,888)(55,029)(32,952)
Other undisclosed operating loss (645) 
Operating loss:(66,388)(55,029)(28,024)
Nonoperating income (expense)1,426571(858)
Other nonoperating expense(38)(74)(967)
Loss from continuing operations before income taxes:(64,962)(54,458)(28,882)
Income tax benefit 191918
Loss from continuing operations:(64,943)(54,439)(28,864)
Loss before gain (loss) on sale of properties:(64,943)(54,439)(28,864)
Net loss available to common stockholders, diluted:(64,943)(54,439)(28,864)

Comprehensive Income ($ in thousands)
Annual | Quarterly

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(64,943)(54,439)(28,864)
Comprehensive loss, net of tax, attributable to parent:(64,943)(54,439)(28,864)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: